A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Wegovy's FDA approval to treat adults with MASH and Galvanize's first patient enrolled in the PROPEL Registry.

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

1. Wegovy^® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
   The accelerated approval is based on Part 1 of the ESSENCE trial, in which Wegovy^® demonstrated a statistically significant improvement in liver fibrosis (liver scarring) with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo.
2. Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity The Phase 2 VENTURE-Oral Dosing trial successfully achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. The study showed VK2735 treatment to be safe and well-tolerated through 13 weeks of daily dosing with most treatment emergent adverse events (TEAEs) being categorized as mild or moderate.
3. Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders The collaboration aims to expand the potential of RNA modulation in diseases where traditional approaches have proven challenging, leveraging Skyhawk's industry-leading capabilities in RNA splicing modulation and Merck KGaA, Darmstadt, Germany's expertise in drug development and commercialization.
4. Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
   Aon plc announced a strategic investment in eMed Population Health, Inc. With this investment, eMed will continue to increase distribution of its digital-first healthcare platform — which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support—to reach more employers and patients.
5. Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer The granting of BTD underscores the strength of these data and highlights the potential of iza-bren to address the significant clinical unmet need patients face after EGFR TKI and platinum-based chemotherapy treatment. While EGFR TKIs have shown clinical efficacy in the frontline setting, most patients eventually see their cancer progress after about 18 months.
6. Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis Precigen will begin promoting PAPZIMEOS immediately and is committed to helping patients with RRP access the therapy. Precigen has established Papzimeos SUPPORT, a comprehensive patient support program offering personalized services, including insurance navigation, financial assistance, and ongoing access support.
7. OpenEvidence creates the first AI in history to score a perfect 100% on the United States Medical Licensing Examination (USMLE) This achievement of becoming the first AI in history to score a perfect 100% on the USMLE is the result of a six-month effort to further evolve the core AI models and other technologies that power OpenEvidence, and demonstrates OpenEvidence's commitment and continued effort to improve physician knowledge at all levels of medical education.
8. Abbott and Big Ten Conference Rally Students, Alumni, and Fans to Save Lives and Win $1 Million for Their School by Donating Blood This College Football Season All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood donations from students, alumni, and fans with the winning school earning $1 million from Abbott for student or community health.
9. Stealth Biotherapeutics Resubmits New Drug Application for Elamipretide for the Treatment of Barth Syndrome As directed by the FDA in its May 2025 complete response (CR) and subsequent correspondence, the resubmission contains no new clinical efficacy data, a minor safety update, and confirmation that previously cited manufacturing deficiencies were resolved by FDA, which determined in July that the facility remains in compliance.
10. Galvanize Announces First Patient Enrolled in the PROPEL Registry Evaluating Aliya^® Pulsed Electric Field Ablation for Soft Tissue Lesions "The PROPEL Registry is an important step in understanding how Aliya performs in a broad, heterogeneous patient population outside of a prospective trial setting," said Dr. Bill Krimsky, Chief Medical Officer at Galvanize. "By systematically capturing procedural data, clinical outcomes, and physician experience, we aim to inform evidence-based integration of our PEF ablation into clinical care pathways."
11. Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease The test offers results that are comparable to existing methods that support a diagnosis of Alzheimer's disease – cerebrospinal fluid (CSF) testing obtained through lumbar puncture and positron emission tomography (PET) scans – but from a simple blood draw, making it more affordable, more accessible and less invasive.
12. Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry The new collaboration connects three core capabilities: (1) Ginkgo Datapoints' rapid ADME profiling, (2) Inductive Bio's model–driven chemistry design platform, and (3) Tangible Scientific's API-enabled compound management platform. Together, these capabilities aim to move from in-silico compound designs to validated experimental results in one digitally-enabled workstream, with fewer synthesis cycles, faster turnarounds, and lower overall drug discovery costs.
13. IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes IQVIA has joined Veeva's CRO Clinical Data Partner program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC. With this partnership, customers will benefit from IQVIA's clinical data management, clinical technology solutions, and EDC programming expertise with Veeva software to accelerate database builds, study locks, and data delivery.
14. San Diego-Area Biotech Startup Achieves Major Breakthrough in the Fight Against Rare Neurodevelopmental Disorder The company's very first patient, Eleanor Elnekaveh, has successfully completed the experimental treatment regimen of RTT-1 (Eleanor), an mRNA lipid nanoparticle (LNP) protein replacement therapy. Eleanor tolerated the therapy well— a critical first step toward making this innovative therapeutic available to more Rett Syndrome patients. 

For more news like this, check out all of the latest health-related releases from PR Newswire.

Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.

Helping Journalists Stay Up to Date on Industry News

These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.

Once they're signed up, reporters, bloggers, and freelancers have access to the following free features:

• Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.
• Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story.
• Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.
• Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.

About PR Newswire

PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

For questions, contact the team at media.relations@cision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/weekly-recap-14-health-press-releases-you-need-to-see-302536261.html

SOURCE PR Newswire